Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of the Booster Dose of Two MenC Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy toddlers of both sexes~* Toddlers of 14 to 19 months of age (including the day that the toddler is 14 and the day before he is 19 months of age)~* Children previously vaccinated with two doses of polysaccharide meningococcal C vaccine conjugated to tetanus toxoid or three doses of polysaccharide meningococcal C conjugated to CRM197 before 7 month of age.~* Informed consent signed by one or both parents who are adequately informed about the study.~Exclusion Criteria:~* Toddlers with severe diseases or axilar temperature ≥ 38,0ºC at inclusion time~* Toddlers with severe chronic diseases~* Toddlers who have received any other vaccine within the last month or with a programmed vaccination within the 28 subsequent days after the administration of the vaccine of study.~* Toddlers with clinical or bacteriological diagnosis of previous meningococcal disease.~* Toddlers with hypersensitivity to any of the components of the vaccines to study or antibiotics used during the manufacturing process that could be present as non- detectable traces (streptomycin, neomycin, polymyxin B).~* Toddlers with personal history of convulsions.~* Toddlers with known bleeding disorder no controlled~* Toddlers with known congenital or acquired immunodeficiency~* Toddlers who are receiving or have been received any treatment that could change the immune response (administration of intravenous immunoglobulin, systemic corticosteroids or haemoderivates) within the 3 previous months.~* A toddler that under investigator opinion is probable to be lost during the follow-up~* A toddler that is currently included or is planned to be included in any other clinical trial.~* A toddler that under investigator opinion must not be included in the study due to other medical or social reasons.

- Gender: ALL
- Minimum Age: 14 Months
- Maximum Age: 19 Months
- Healthy Volunteers: t

Study Arms:
- MENC-CRM/MENC-CRM (Type: EXPERIMENTAL): Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
- MENC-CRM/MENC-TT (Type: EXPERIMENTAL): Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
- MENC-TT/MENC-CRM (Type: EXPERIMENTAL): Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
- MENC-TT/MENC-TT (Type: EXPERIMENTAL): Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).